TTP-8307

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H130415

CAS#: 950225-08-8

Description: TTP-8307 inhibits viral replication, specifically inhibiting the activity of the oxysterol-binding protein (OSBP) through the PI4KIIIβ-PI4P-OSBP pathway.

Chemical Structure

img
TTP-8307
CAS# 950225-08-8
Instruction

Theoretical Analysis

Hodoodo Cat#: H130415
Name: TTP-8307
CAS#: 950225-08-8
Chemical Formula: C27H21FN4O
Exact Mass: 436.17
Molecular Weight: 436.490
Elemental Analysis: C, 74.30; H, 4.85; F, 4.35; N, 12.84; O, 3.67

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: TTP-8307; TTP8307; TTP 8307

IUPAC/Chemical Name: (R)-N-(1-(4-fluorophenyl)ethyl)-3-(2-(isoquinolin-3-yl)-1H-imidazol-5-yl)benzamide

InChi Key: SIBDJDZVNXVLEX-QGZVFWFLSA-N

InChi Code: InChI=1S/C27H21FN4O/c1-17(18-9-11-23(28)12-10-18)31-27(33)21-8-4-7-20(13-21)25-16-30-26(32-25)24-14-19-5-2-3-6-22(19)15-29-24/h2-17H,1H3,(H,30,32)(H,31,33)/t17-/m1/s1

SMILES Code: O=C(N[C@@H](C1=CC=C(F)C=C1)C)C2=CC=CC(C3=CN=C(C4=CC5=C(C=N4)C=CC=C5)N3)=C2

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 436.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Roberts BL, Severance ZC, Bensen RC, Le-McClain AT, Malinky CA, Mettenbrink EM, Nuñez JI, Reddig WJ, Blewett EL, Burgett AWG. Differing activities of oxysterol-binding protein (OSBP) targeting anti-viral compounds. Antiviral Res. 2019 Oct;170:104548. doi: 10.1016/j.antiviral.2019.104548. Epub 2019 Jul 2. PMID: 31271764.


2: Albulescu L, Bigay J, Biswas B, Weber-Boyvat M, Dorobantu CM, Delang L, van der Schaar HM, Jung YS, Neyts J, Olkkonen VM, van Kuppeveld FJM, Strating JRPM. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307. Antiviral Res. 2017 Apr;140:37-44. doi: 10.1016/j.antiviral.2017.01.008. Epub 2017 Jan 11. PMID: 28088354.


3: Norder H, De Palma AM, Selisko B, Costenaro L, Papageorgiou N, Arnan C, Coutard B, Lantez V, De Lamballerie X, Baronti C, Solà M, Tan J, Neyts J, Canard B, Coll M, Gorbalenya AE, Hilgenfeld R. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res. 2011 Mar;89(3):204-18. doi: 10.1016/j.antiviral.2010.12.007. Epub 2011 Jan 12. PMID: 21236302.


4: Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol. 2011 Mar;85(5):2364-72. doi: 10.1128/JVI.02249-10. Epub 2010 Dec 22. PMID: 21177810; PMCID: PMC3067798.


5: Arita M, Takebe Y, Wakita T, Shimizu H. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. J Gen Virol. 2010 Nov;91(Pt 11):2734-44. doi: 10.1099/vir.0.023374-0. Epub 2010 Jul 21. PMID: 20660150.


6: Aguado L, Thibaut HJ, Priego EM, Jimeno ML, Camarasa MJ, Neyts J, Pérez-Pérez MJ. 9-Arylpurines as a novel class of enterovirus inhibitors. J Med Chem. 2010 Jan 14;53(1):316-24. doi: 10.1021/jm901240p. PMID: 19924996.


7: De Palma AM, Thibaut HJ, van der Linden L, Lanke K, Heggermont W, Ireland S, Andrews R, Arimilli M, Al-Tel TH, De Clercq E, van Kuppeveld F, Neyts J. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother. 2009 May;53(5):1850-7. doi: 10.1128/AAC.00934-08. Epub 2009 Feb 23. PMID: 19237651; PMCID: PMC2681499.